Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 726 - 750 of 8873 in total
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Approved
Investigational
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Description: … It is currently under development as topical treatment of psoriasis. ... Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of ... This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection …
Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and...
Approved
Investigational
Matched Description: … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of
Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to...
Approved
Matched Description: … Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of ... is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of ... ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS …
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … and nonallergic forms of asthma where eosinophilia is prominent. ... cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of ... Elevated levels of eosinophils increase the risk for asthma exacerbations, including both allergic forms …
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Description: … 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. ... formulation of CTLA4-Ig into clinical trials (RG2077). ... antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin …
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell ... [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126 …
Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. Actinic keratosis is a chronic condition characterized...
Approved
Investigational
Matched Description: … Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. ... [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic ... Tirbanibulin blocks the molecular pathways that promote the proliferation, survival, and metastasis of
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic...
Approved
Investigational
Matched Description: … leukaemia (ALL), only after at least two other types of treatment have failed. ... Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. ... Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic …
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including...
Approved
Matched Description: … of phentolamine. ... prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue ... anesthesia, and treatment of pharmacologically-induced mydriasis. …
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. …
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to...
Approved
Investigational
Matched Description: … Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily ... downstream modulation of both gonadotropin hormone and sex steroid levels. ... Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). …
Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of...
Approved
Vet approved
Matched Description: … The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of ... of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues ... The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating …
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … antibodies were important for therapeutic benefit in animal models of EBOV infection. ... _ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of ... [A222078] The chief surface target of EBOV particles is the GP1,2 glycoprotein, which also …
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … antibodies were important for therapeutic benefit in animal models of EBOV infection. ... _ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of ... [A222078] The chief surface target of EBOV particles is the GP1,2 glycoprotein, which also …
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which...
Approved
Investigational
Matched Description: … [L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of ... weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of ... [A179449] Deflazacort delays the onset of muscle related complications resulting from DMD[A179455] …
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … [L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody …
Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in...
Approved
Investigational
Matched Description: … of extensive deformities or in the treatment of other forms of arthritis. ... Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold ... It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence …
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Approved
Matched Description: … It is a member of the serpin superfamily. ... A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and …
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It...
Approved
Matched Description: … Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial ... retinopathy of prematurity in preterm infants in February 2023 and for the treatment of wet age-related ... growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin …
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in...
Approved
Investigational
Matched Description: … the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of
Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about...
Approved
Nutraceutical
Vet approved
Matched Description: … Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors ... of melatonin synthesis. ... the circadian rhythms of several biological functions, including the sleep-wake cycle. …
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available...
Approved
Matched Description: … Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. ... Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus …
Indigotindisulfonic acid is a blue-colored dye with a variety of uses.[A32490,A32491,A32492,L2222] Its salt form, indigotindisulfonate sodium, is also known as indigo carmine, indigotine or FD&C Blue #2. This compound is an acid-base indicator and is used in the production of food colorants and pH tests. Indigotindisulfonic acid is used in...
Approved
Investigational
Matched Description: … Indigotindisulfonic acid is a blue-colored dye with a variety of uses. ... This compound is an acid-base indicator and is used in the production of food colorants and pH tests. ... [A32490,A32491,A32492] In 2022, the FDA approved the intravenous use of indigotindisulfonate sodium to …
Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. Neurotrophic keratitis is a...
Approved
Investigational
Matched Description: … The loss of corneal sensation impairs corneal health, causing progressive damage to the top layer of ... [L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition ... the treatment, diagnosis or prevention of a serious condition. …
Displaying drugs 726 - 750 of 8873 in total